CHINA ULCERATIVE COLITIS MARKET ANALYSIS

China Ulcerative Colitis Market, by Drug Therapy (5-Aminosalicylates {Mesalazine, Balsalazide, Olsalazine, and Others}, Monoclonal Antibodies {Vedolizumab, Adalimumab, Infliximab, Golimumab, and Ustekinumab}, Steroids {Budesonide, Prednisone, Beclomethasone, Deflazacort, and Others}, Antibiotics, Late Stage Pipeline Molecules {Zeposia, Etrasimod and Others}, and Other Drugs), by Dosage Form (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : May 2022
Code : CMI4862
Pages :408
Formats :
Excel and PDF
Industry : Pharmaceutical

China Ulcerative Colitis MarketSize and Trends

The China ulcerative colitis market is estimated to be valued at US$ 246.3 Mn in 2022 and is expected to exhibit a CAGR of 3.3% over the forecast period (2022-2030)

Figure 1: China Ulcerative Colitis Market Share, (%), Analysis, By Drug Therapy, 2022

Market players are indulged in conducting research and development activities, in order to develop innovative treatment for ulcerative colitis. This is expected to drive growth of the China ulcerative colitis market over the forecast period.

Figure 2: China Ulcerative Colitis Market Value (US$ Mn) & Y-o-Y Growth (%), 2022 – 2030